肿瘤防治研究2023年第50卷第4期Cancer Res Prev Treat,.2023,ol.50,No.4·427·dbi:10.3971h.issn.1000-8578.2023.22.1287·指南与解读·基于多学科诊疗的《皮肤基底细胞癌诊疗专家共识（2021)》解读王宏兵'，王满香2”，万立3，蔡微娜，陈金波，皮国良Interpretation of Expert Consensus on Diagnosis and Treatment of Cutaneous Basal CellCarcinoma(2021)by A Multidisciplinary TeamWANG Hongbing',WANG Manxiang",WAN Li,CAI Weina',CHEN Jinbo',PI Guoliang(*Contributed Equally as the First Author)1.Department of Gynecology and Oncology.Hubei Cancer Hospital,Wuhan 430079.China:2.Department of Pathology:Hubei Cancer Hospital,Wuhan 430079,China:3.Departmentof Dermatology,Dermatology Hospital of Southern Medical University:Guanghou 510091,China:4.Department of Dermatology.Wuhan No.I Hospital,Wuhan 430022,China:5.Centerof Radiation Oncology.Hubei Cancer Hospital.Wuhan 430079.ChinaCorresponding Author:PI Guoliang.E-mail:piguoliang_2004@163.comAbstraet:Basal cell carcinoma (BCC)is the most common malignant tumor in dermatology with incidence risingrapidly.Expert consensus on diagnosis and treatment of cutaneous basal cell carcinoma (2021)was publishedin September 2021 by Skin Tumor Research Center,Chinese Society of Dermatology and Subcommittee onSkin Tumor,China Der matologist Association.This consensus comprehensively describes the epidemiology,pathogenesis,clinical manifestations,auxil iary examination,pathology,pretreatment assessment,treatment,prognosis,and follow-up education.It offers an important guideline for promoting the standardized diagnosisand treatment of skin BCC in China.In this work,multidisciplinary experts interpreted the main contents of theconsensus,including clinicopathological findings,pretreatment assessment,andtreatment advanceKey words:Basal cell carcinoma;Skin;Multidisciplinary team;Interpretation of consensusFunding:The 7th Wuhan Young and Middle-aged Backbone Talent of Medical Training Project 2019 (2019 No.87)Competing interests:The authors declare that they have no competing interests.摘要：基底细胞癌是最常见的皮肤恶性肿编，且发病率呈快速上升趋势，2021年9月，中华医学会皮肤性病学分会皮肤肿璃研究中心、中国医师协会皮肤科医师分会皮肤肿璃学组发布《皮肤基底细胞癌诊疗专家共识(2021)》。本共识从基底细胞癌的流行病学、发病机制、临床表现、辅助检查、病理、治疗前评估、治疗、预后及随访宣教多个方面进行了阐谜，对促进我国皮肤基底细胞癌惠者的规范化珍疗具有重要指导意义。本文将基于多学科珍疗对本共识中重点内客包括临床病理表现、治疗前评估及治疗进晨等进行详细解读。关键词：基底细胞癌；皮肤；多学科诊疗；共识解读中图分类号：R739.5开放科学资源服务标识码(OSID):0引言收稿日期：2022-11-02；修回日期：2023-01-01基底细胞癌(basal cell carcinoma,.BCC)是最基金项目：2019年度武汉市第七批中青年医学骨千人常见的皮肤恶性肿瘤，多数生长缓慢，较少转移，才培茶工程项目（武卫通〔2019〕87号）作者单位：1.430079武汉，湖北省肿璃医院妇璃科：但部分病例可浸润破坏组织和器官，引起器官功2.430079武汉，湖北省肿璃医院病理科：3.510091广州，能障碍，甚至危及患者生命。因此，对BCC尤其是南方医科大学皮肤病医院皮肤科；4.430022武汉，武汉市第高危型BCC的早期筛查及规范化诊疗迫在眉睫。一医院皮肤科；5.430079武汉，湖北省肿璃医院放疗中心通信作者：皮国良(1981-)，博士，副主任医师，国内外有多个针对BCC的共识和指南，除了主要从事恶性肿璃放化疗及免疫粑向治疗研究，E-mi:本共识中参考的《BCC临床实践指南2021.2版》、piguoliang_2004@163.com,ORCID:0000-0002-2740-2857《欧洲基底细胞癌诊疗共识》(2019版)、作者简介：王宏兵(1987-)，男，硕士，主治医师，主要从事妇科恶性肿璃放射治疗研究，ORCID:《WHO皮肤肿瘤分类》(2018版)、《加拿大非0009-0006-1689-5605;王满香(1981-)，女，博士，主治医黑色素瘤皮肤癌指南》(2015版)外，还有美国师，主要从事肿骗病理及分子病理研究（◆：并列第一作者）皮肤病学会杂志发布了《BCC治疗指南》(2018(C)1994-2023 China Academic Journal Electronic Publishing House.All rights reserved.htt
